These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 1531363)
1. Pharmacological characterization of 5-hydroxytryptamine-induced apnea in the rat. Yoshioka M; Goda Y; Togashi H; Matsumoto M; Saito H J Pharmacol Exp Ther; 1992 Feb; 260(2):917-24. PubMed ID: 1531363 [TBL] [Abstract][Full Text] [Related]
2. [Ventilatory mechanical analysis of respiratory depression induced by serotonin]. Goda Y Hokkaido Igaku Zasshi; 1993 Jan; 68(1):29-41. PubMed ID: 8444402 [TBL] [Abstract][Full Text] [Related]
3. Effect of a novel 5-hydroxytryptamine3-antagonist, GR38032F, on the 5-hydroxytryptamine-induced increase in carotid sinus nerve activity in rats. Yoshioka M J Pharmacol Exp Ther; 1989 Aug; 250(2):637-41. PubMed ID: 2527299 [TBL] [Abstract][Full Text] [Related]
4. Effect of 5-hydroxytryptamine on external carotid nerve activity and its blockade by GR38032F in anesthetized rats. Yoshioka M; Ikeda T; Abe M; Togashi H; Saito H Res Commun Chem Pathol Pharmacol; 1991 Oct; 74(1):39-45. PubMed ID: 1839326 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of 5-hydroxytryptamine-induced excitation of afferent cervical vagus nerve in anaesthetized rats. Yoshioka M; Ikeda T; Abe M; Togashi H; Minami M; Saito H Br J Pharmacol; 1992 Jul; 106(3):544-9. PubMed ID: 1387026 [TBL] [Abstract][Full Text] [Related]
6. Species difference in the 5-hydroxytryptamine3 receptor associated with the von Bezold-Jarisch reflex. Yamano M; Ito H; Kamato T; Miyata K Arch Int Pharmacodyn Ther; 1995; 330(2):177-89. PubMed ID: 8861711 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. Nagakura Y; Kadowaki M; Tokoro K; Tomoi M; Mori J; Kohsaka M J Pharmacol Exp Ther; 1993 May; 265(2):752-8. PubMed ID: 8496821 [TBL] [Abstract][Full Text] [Related]
8. Effect of 5-hydroxytryptamine3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices. Edwards E; Harkins K; Ashby CR; Wang RY J Pharmacol Exp Ther; 1991 Mar; 256(3):1025-32. PubMed ID: 1848625 [TBL] [Abstract][Full Text] [Related]
9. Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential-reinforcement-of-low-rate 72-second schedule. Marek GJ; Seiden LS J Pharmacol Exp Ther; 1988 Feb; 244(2):650-8. PubMed ID: 2894458 [TBL] [Abstract][Full Text] [Related]
10. 5-HT induces enhanced phrenic nerve activity via 5-HT(2A) receptor/PKC mechanism in anesthetized rats. Liu J; Wei X; Zhao C; Hu S; Duan J; Ju G; Wong-Riley MT; Liu Y Eur J Pharmacol; 2011 Apr; 657(1-3):67-75. PubMed ID: 21296069 [TBL] [Abstract][Full Text] [Related]
11. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. Lucki I; Nobler MS; Frazer A J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097 [TBL] [Abstract][Full Text] [Related]
12. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro. Germonpré PR; Joos GF; Pauwels RA Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery. Hamel E; Robert JP; Young AR; MacKenzie ET J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Prins NH; Akkermans LM; Lefebvre RA; Schuurkes JA Br J Pharmacol; 2001 Nov; 134(6):1351-9. PubMed ID: 11704657 [TBL] [Abstract][Full Text] [Related]
15. Characterization of putative 5-HT7 receptors mediating tachycardia in the cat. Villalón CM; Heiligers JP; Centurión D; De Vries P; Saxena PR Br J Pharmacol; 1997 Jul; 121(6):1187-95. PubMed ID: 9249256 [TBL] [Abstract][Full Text] [Related]
16. Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. Ito H; Hidaka K; Miyata K; Kamato T; Nishida A; Honda K J Pharmacol Exp Ther; 1992 Dec; 263(3):1127-32. PubMed ID: 1469624 [TBL] [Abstract][Full Text] [Related]
17. 5-HT activates vagal afferent cell bodies in vivo: role of 5-HT2 and 5-HT3 receptors. Lacolley P; Owen JR; Sandock K; Lewis TH; Bates JN; Robertson TP; Lewis SJ Neuroscience; 2006 Nov; 143(1):273-87. PubMed ID: 17029799 [TBL] [Abstract][Full Text] [Related]
18. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity. Millan MJ; Bervoets K; Colpaert FC J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of 5-hydroxytryptamine2 and 5-hydroxytryptamine3 receptors in rat dorsal root ganglion cells. Todorovic SM; Anderson EG J Pharmacol Exp Ther; 1990 Jul; 254(1):109-15. PubMed ID: 2366178 [TBL] [Abstract][Full Text] [Related]
20. Serotonin-induced vasoconstriction in dog kidney. Takahashi T; Hisa H; Satoh S J Cardiovasc Pharmacol; 1992; 20(5):779-84. PubMed ID: 1280741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]